|
|
News Breaks | | | | November 13, 2012 | | 07:18 EDT |  | CCXI | ChemoCentryx reports Q3 EPS (28c), consensus (22c)
Reports Q3 revenue $1.13M, consensus $4.75M | |
|
News For CCXI From The Last 14 Days Check below for free stories on CCXI the last two weeks. |
|
|
| May 20, 2013 | | 07:27 EDT |  | CCXI | ChemoCentryx shares should be bought ahead of 2H13 events, says Stifel
After attending ChemoCentryx's R&D Day, Stifel thinks the company has several upcoming significant catalysts, including Phase III data on its Crohn's disease treatment, Vercirnon, that the firm expects to be positive. The firm raised its price target on the stock to $20 from $16 and keeps a Buy rating on the shares. | | | May 15, 2013 | | 15:43 EDT |  | CCXI | ChemoCentryx to host analyst meeting
 Subscribe for More Information | | | May 14, 2013 | | 07:18 EDT | | CCXI | BofA/Merrill to host a conference
2013 Health Care Conference is being held in Las Vegas on May 14-16. | | | May 13, 2013 | | 16:19 EDT | | CCXI | ChemoCentryx reports Q1 EPS (28c), consensus (27c)
Subscribe for More Information | |
|
|
|
|
|
|
